New dosing strategy for MS drug ublituximab under study in 800-Patient trial

NCT ID NCT05877963

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial is testing a modified dosing schedule of ublituximab (BRIUMVI) in 800 people with relapsing multiple sclerosis. The study has three parts: one open-label part to see if the new regimen reduces brain lesions, a placebo-controlled part to measure drug levels, and another open-label part for those who had a poor response to prior anti-CD20 therapy. The goal is to find a safer or more effective way to control MS relapses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ublituximab (BRIUMVI)

What this could lead to

If successful, this could offer a more effective or convenient dosing schedule for ublituximab to control relapsing multiple sclerosis.

What could go wrong

This is a Phase 3 study, but results may not confirm benefit over existing treatments. Infusion-related reactions and other side effects are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • TG Investigational Site

    RECRUITING

    Fort Collins, Colorado, 80528, United States

  • TG Investigational Site

    RECRUITING

    Farmington, Michigan, 48334, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Birmingham, Alabama, 35209, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Cullman, Alabama, 35058, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Orange, California, 92697, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Washington D.C., District of Columbia, 20007, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Tampa, Florida, 33612, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Savannah, Georgia, 31406, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Chicago, Illinois, 60612, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Indianapolis, Indiana, 46256, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Iowa City, Iowa, 52242, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Overland Park, Kansas, 66212, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Lutherville, Maryland, 21093, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Boston, Massachusetts, 00002, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Foxborough, Massachusetts, 02035, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    North Worcester, Massachusetts, 01655, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Wellesley, Massachusetts, 02481uni, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Golden Valley, Minnesota, 55422, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Plymouth, Minnesota, 55446, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    St Louis, Missouri, 63131, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    New York, New York, 10025, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    New York, New York, 11021, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Raleigh, North Carolina, 27607, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Dayton, Ohio, 45417, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Greenville, South Carolina, 29605, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Knoxville, Tennessee, 37922, United States

  • TG Therapeutics Investigational Trial Site

    ACTIVE_NOT_RECRUITING

    Houston, Texas, 77030, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Salt Lake City, Utah, 84103, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Vienna, Virginia, 22182, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Kirkland, Washington, 98034, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Seattle, Washington, 98109, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Spokane, Washington, 99208, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Bydgoszcz, Poland

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Katowice, 40-555, Poland

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Katowice, Poland

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Kielce, Poland

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Krakow, 31-826, Poland

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Lodz, Poland

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Olsztyn, 10-561, Poland

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Poznan, Poland

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Warsaw, 04-141, Poland

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Zabrze, Poland

  • TG Therapeutics Investigational Trial Site

    RECRUITING

    Żory, 44-240, Poland

  • TG Therapeutics Investigational Trial SiteCharlotte

    RECRUITING

    Charlotte, North Carolina, 28204, United States